124 related articles for article (PubMed ID: 36933699)
1. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer.
Liang X; Yang Y; Huang C; Ye Z; Lai W; Luo J; Li X; Yi X; Fan JB; Wang Y; Wang Y
J Control Release; 2023 Apr; 356():691-701. PubMed ID: 36933699
[TBL] [Abstract][Full Text] [Related]
2. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
[TBL] [Abstract][Full Text] [Related]
3. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
4. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
Xu Q; Liu Y; Wang S; Wang J; Liu L; Xu Y; Qin Y
BMC Cancer; 2022 Jun; 22(1):628. PubMed ID: 35672728
[TBL] [Abstract][Full Text] [Related]
5. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
6. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
7. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin.
Zhu J; Lin S; Zou X; Chen X; Liu Y; Yang X; Gao J; Zhu H
Mol Biol Rep; 2023 Aug; 50(8):6457-6468. PubMed ID: 37326754
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance.
Zhang Y; Dong Y; Fu H; Huang H; Wu Z; Zhao M; Yang X; Guo Q; Duan Y; Sun Y
Biomaterials; 2021 Feb; 269():120478. PubMed ID: 33213862
[TBL] [Abstract][Full Text] [Related]
10. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
11. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
Zhang J; Bai HJ
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
[No Abstract] [Full Text] [Related]
12. A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin.
Guo X; Fang Z; Zhang M; Yang D; Wang S; Liu K
Molecules; 2020 Jun; 25(11):. PubMed ID: 32512936
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
14. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
15. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
Gong S; Chen Y; Meng F; Zhang Y; Wu H; Li C; Zhang G
FASEB J; 2019 Apr; 33(4):5350-5365. PubMed ID: 30768358
[TBL] [Abstract][Full Text] [Related]
16. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer.
Li L; He D; Guo Q; Zhang Z; Ru D; Wang L; Gong K; Liu F; Duan Y; Li H
J Nanobiotechnology; 2022 Jan; 20(1):50. PubMed ID: 35078498
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
18. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
19. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
